This course has expired. View available courses.
Endocrinology
Expert Narratives in Cardiovascular Disease and Antihyperglycemic Therapy
This continuing education program is designed to provide clinicians with a review of the current cardiovascular outcome trials (CVOTs) for antihyperglycemic agents. The goal is to ensure clinicians have the most current data to ensure their patients are optimally protected from major adverse cardiovascular events (MACE).
DURATION
1 hour
PROFESSION
Physician
# OF CREDITS
1
ACCREDITATION
Mainpro+
EXPIRY DATE
2021-10-01
This continuing education program is
designed to provide clinicians with a review of the current cardiovascular
outcome trials (CVOTs) for antihyperglycemic agents. The goal is to ensure
clinicians have the most current data to ensure their patients are optimally
protected from major adverse cardiovascular events (MACE).
Faculty
- Alice Y. Y. Cheng, MD, FRCPC
- James Kim, MBBch
- Jeff Habert, MD, CCFP, FCFP
- John Axler, MD, CCFP, FCFP
- Pierre Filteau, MD
Learning objectives
Upon completion of this continuing education program clinicians will be better able to:
- Discuss the practical application of screening patients with T2DM for cardiovascular and renal risk factors
- Describe how the patient populations in the antihyperglycemic cardiovascular outcome trials differ from one another and the clinical significance of these differences
- Review key considerations in the antihyperglycemic agent selection in patients with established cardiovascular disease, renal disease or multiple cardiovascular risk factors
- Develop a cardioprotective treatment plan for patients with type 2 diabetes and one of the following:
- Established cardiovascular disease
- Renal disease
- Multiple cardiovascular risk factors